Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2004 3
2005 2
2006 3
2008 2
2009 3
2010 2
2011 6
2012 3
2013 9
2014 10
2015 12
2016 7
2017 6
2018 11
2019 5
2020 3
2021 1
2022 4
2023 3
2024 4
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials.
Chang HY, Li YY, Hong CT, Kuan YC. Chang HY, et al. J Psychopharmacol. 2022 Jun;36(6):704-714. doi: 10.1177/02698811221093795. Epub 2022 May 12. J Psychopharmacol. 2022. PMID: 35546511
BACKGROUND: Rasagiline monotherapy is approved in early Parkinson's disease (PD) for motor benefit. However, the efficacy and optimal rasagiline dosage in improving Unified Parkinson's Disease Rating Scale (UPDRS) subscale scores between Japanese and Caucasian indiv …
BACKGROUND: Rasagiline monotherapy is approved in early Parkinson's disease (PD) for motor benefit. However, the efficacy and optimal …
Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J. Mínguez-Mínguez S, et al. Pharmacol Res. 2013 Aug;74:78-86. doi: 10.1016/j.phrs.2013.05.005. Epub 2013 Jun 2. Pharmacol Res. 2013. PMID: 23735235 Review.
In this review, we compare the efficacy of rasagiline versus placebo for decreasing PD symptoms. Major databases (Medline, the Cochrane Library) were systematically searched to identify and select clinical randomized control trials of rasagiline. ...Rasagiline …
In this review, we compare the efficacy of rasagiline versus placebo for decreasing PD symptoms. Major databases (Medline, the Cochra …
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
Chang Y, Wang LB, Li D, Lei K, Liu SY. Chang Y, et al. Ann Med. 2017 Aug;49(5):421-434. doi: 10.1080/07853890.2017.1293285. Epub 2017 Mar 15. Ann Med. 2017. PMID: 28293967 Review.
OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B. The aim of the study was to analyze the effectiveness of rasagiline in treatment of Parkinson's disease (PD), both as monotherapy and combination therapy. ...CONCLUSIONS: …
OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B. The aim of the study was to analyze t …
Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
Solís-García del Pozo J, Mínguez-Mínguez S, de Groot PW, Jordán J. Solís-García del Pozo J, et al. Expert Opin Drug Saf. 2013 Jul;12(4):479-86. doi: 10.1517/14740338.2013.790956. Epub 2013 May 2. Expert Opin Drug Saf. 2013. PMID: 23634791
AREAS COVERED: This article reviews the reported adverse effects of rasagiline. A MEDLINE search was performed for all articles from 1990 to present, which reported any adverse effects from rasagiline or related references. We conducted an analysis of the adverse ef …
AREAS COVERED: This article reviews the reported adverse effects of rasagiline. A MEDLINE search was performed for all articles from …
Comparative efficacy and safety of irreversible (rasagiline) and reversible (safinamide) monoamine oxidase inhibitors as add-on therapy for Parkinson's disease.
Khalid MB, Shahzad F, Siddiqui MR, Abedin MZU, Hulou S, Shami B, Ahmed SI. Khalid MB, et al. J Neurol. 2025 Jul 1;272(7):486. doi: 10.1007/s00415-025-13230-w. J Neurol. 2025. PMID: 40590994
BACKGROUND: Parkinson's disease (PD) is a progressive, neurodegenerative condition caused by progressive loss of dopaminergic neurons of the substantia nigra. Safinamide and rasagiline are both novel medications that are indicated for PD. Safinamide (reversible) and ras …
BACKGROUND: Parkinson's disease (PD) is a progressive, neurodegenerative condition caused by progressive loss of dopaminergic neurons of the …
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.
Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. Statland JM, et al. Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26. Muscle Nerve. 2019. PMID: 30192007 Free PMC article. Clinical Trial.
RESULTS: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerat …
RESULTS: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical contr …
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
Hauser RA, Abler V, Eyal E, Eliaz RE. Hauser RA, et al. Int J Neurosci. 2016 Oct;126(10):942-6. doi: 10.3109/00207454.2016.1154552. Epub 2016 Mar 18. Int J Neurosci. 2016. PMID: 26988747
AIM OF THE STUDY: To evaluate the efficacy of rasagiline versus placebo in a pooled population of patients with early Parkinson's disease (PD). ...The present analysis includes all patients who received rasagiline 1 mg/day, 2 mg/day or placebo, and had 1 post-basel …
AIM OF THE STUDY: To evaluate the efficacy of rasagiline versus placebo in a pooled population of patients with early Parkinson's dis …
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
Hattori N, Takeda A, Takeda S, Nishimura A, Kitagawa T, Mochizuki H, Nagai M, Takahashi R. Hattori N, et al. Parkinsonism Relat Disord. 2019 Mar;60:146-152. doi: 10.1016/j.parkreldis.2018.08.024. Epub 2018 Sep 1. Parkinsonism Relat Disord. 2019. PMID: 30205936 Free article. Clinical Trial.
BACKGROUND: Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson's disease (PD). ...The change from baseline in the MDS-UPDRS Part II + III TS was significantly greater in the rasagiline vs. placebo group (rasagiline-placeb …
BACKGROUND: Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson's disease (PD). ...The change fr …
Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
Cai JP, Chen WJ, Lin Y, Cai B, Wang N. Cai JP, et al. Eur Neurol. 2015;73(1-2):5-12. doi: 10.1159/000367892. Epub 2014 Oct 29. Eur Neurol. 2015. PMID: 25358603
BACKGROUND: To assess the safety and efficacy of rasagiline for the treatment of Parkinson's disease (PD) among individuals currently receiving levodopa. METHODS: A systematic literature search was conducted to identify randomised controlled trials (RCT) comparing rasag …
BACKGROUND: To assess the safety and efficacy of rasagiline for the treatment of Parkinson's disease (PD) among individuals currently …
Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson's disease patients with a matching adjusted indirect comparison.
Tan Y, Wei Q, Xu P, Tao E, Wang L, Cattaneo C, Shang H, Chen S. Tan Y, et al. Sci Rep. 2025 Mar 26;15(1):10502. doi: 10.1038/s41598-025-94960-9. Sci Rep. 2025. PMID: 40140610 Free PMC article. Clinical Trial.
Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson's Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline …
Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson's Disease (PD). However, there remains a s …
86 results